Shares of OncoCyte Co. (NYSEAMERICAN:OCX – Get Rating) have been given an average rating of “Buy” by the six analysts that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target […]
OncoCyte (NYSEAMERICAN:OCX – Get Rating) had its price objective reduced by equities research analysts at Piper Sandler from $1.80 to $1.40 in a research report issued on Sunday, The Fly reports. Piper Sandler’s price objective suggests a potential upside of 23.89% from the company’s current price. Several other equities analysts also recently weighed in on […]
Shares of OncoCyte Co. (NYSEAMERICAN:OCX – Get Rating) have earned an average rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price target among brokers […]
OncoCyte Co. (NYSEAMERICAN:OCX – Get Rating) CEO Ronald Asbury Andrews bought 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 16th. The stock was purchased at an average price of $1.28 per share, for a total transaction of $64,000.00. The transaction was disclosed in a filing with the Securities & […]